Abstract
Objective: The aim was to investigate the serum levels of growth hormone releasing hormone and GH in patients with lung carcinoma. Design: After an overnight fast a plasma sample was collected for determination of growth hormone releasing hormone and GH. Patients: The investigation was performed in 28 patients with non small cell lung carcinoma, in 44 patients with small cell lung carcinoma, and 10 patients with non malignant lung disease. A group of 37 normal subjects served as control. Measurements: Growth hormone releasing hormone and GH were determined by radioimmunoassay. Results: Patients with small cell lung carcinoma showed higher plasma growth hormone releasing hormone levels (49 ± 9.4 ng/l) than control subjects (16.3 ± 2.1 ng/l; P <0.05), patients with non small cell lung carcinoma (23.9 ± 8.8 ng/l; P <0.05), and patients with non malignant lung disease (12.7 ± 5.5; P <0.05). Basal GH level was lower in 5 μg/l in all patients except five patients with small cell lung carcinoma and one patient with non small cell lung carcinoma. Conclusions: The higher plasma growth hormone releasing hormone levels in patients with small cell lung carcinoma compared to normal controls and patients with non small cell lung carcinoma and patients with non malignant lung disease, confirm the frequent neuroendocrine activity of this particular tumour.
| Original language | English |
|---|---|
| Pages (from-to) | 463-467 |
| Number of pages | 5 |
| Journal | Clinical Endocrinology |
| Volume | 34 |
| Issue number | 6 |
| Publication status | Published - 1991 |
Fingerprint
ASJC Scopus subject areas
- Endocrinology
Cite this
Plasma growth hormone (GH)-releasing hormone levels in patients with lung carcinoma. / Schopohl, J.; Losa, M.; Frey, C.; Wolfram, G.; Huber, R.; Permanetter, W.; Von Pawel, J.; Muller, O. A.; Von Werder, K.
In: Clinical Endocrinology, Vol. 34, No. 6, 1991, p. 463-467.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Plasma growth hormone (GH)-releasing hormone levels in patients with lung carcinoma
AU - Schopohl, J.
AU - Losa, M.
AU - Frey, C.
AU - Wolfram, G.
AU - Huber, R.
AU - Permanetter, W.
AU - Von Pawel, J.
AU - Muller, O. A.
AU - Von Werder, K.
PY - 1991
Y1 - 1991
N2 - Objective: The aim was to investigate the serum levels of growth hormone releasing hormone and GH in patients with lung carcinoma. Design: After an overnight fast a plasma sample was collected for determination of growth hormone releasing hormone and GH. Patients: The investigation was performed in 28 patients with non small cell lung carcinoma, in 44 patients with small cell lung carcinoma, and 10 patients with non malignant lung disease. A group of 37 normal subjects served as control. Measurements: Growth hormone releasing hormone and GH were determined by radioimmunoassay. Results: Patients with small cell lung carcinoma showed higher plasma growth hormone releasing hormone levels (49 ± 9.4 ng/l) than control subjects (16.3 ± 2.1 ng/l; P <0.05), patients with non small cell lung carcinoma (23.9 ± 8.8 ng/l; P <0.05), and patients with non malignant lung disease (12.7 ± 5.5; P <0.05). Basal GH level was lower in 5 μg/l in all patients except five patients with small cell lung carcinoma and one patient with non small cell lung carcinoma. Conclusions: The higher plasma growth hormone releasing hormone levels in patients with small cell lung carcinoma compared to normal controls and patients with non small cell lung carcinoma and patients with non malignant lung disease, confirm the frequent neuroendocrine activity of this particular tumour.
AB - Objective: The aim was to investigate the serum levels of growth hormone releasing hormone and GH in patients with lung carcinoma. Design: After an overnight fast a plasma sample was collected for determination of growth hormone releasing hormone and GH. Patients: The investigation was performed in 28 patients with non small cell lung carcinoma, in 44 patients with small cell lung carcinoma, and 10 patients with non malignant lung disease. A group of 37 normal subjects served as control. Measurements: Growth hormone releasing hormone and GH were determined by radioimmunoassay. Results: Patients with small cell lung carcinoma showed higher plasma growth hormone releasing hormone levels (49 ± 9.4 ng/l) than control subjects (16.3 ± 2.1 ng/l; P <0.05), patients with non small cell lung carcinoma (23.9 ± 8.8 ng/l; P <0.05), and patients with non malignant lung disease (12.7 ± 5.5; P <0.05). Basal GH level was lower in 5 μg/l in all patients except five patients with small cell lung carcinoma and one patient with non small cell lung carcinoma. Conclusions: The higher plasma growth hormone releasing hormone levels in patients with small cell lung carcinoma compared to normal controls and patients with non small cell lung carcinoma and patients with non malignant lung disease, confirm the frequent neuroendocrine activity of this particular tumour.
UR - http://www.scopus.com/inward/record.url?scp=0025822261&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0025822261&partnerID=8YFLogxK
M3 - Article
VL - 34
SP - 463
EP - 467
JO - Clinical Endocrinology
JF - Clinical Endocrinology
SN - 0300-0664
IS - 6
ER -